Latest News
09-04-18 Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) 09-04-18 Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome 08-30-18 Zogenix Announces New Data on Psychological and Socioeconomic Impact of Dravet Syndrome and Other Epileptic Encephalopathies at 13th European Congress on Epileptology more »Spotlight on Clinical Studies
The Zogenix study entitled "A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Audlts with Lennox-Gastaut Syndrome" is being conducted for patients with Lennox-Gastaut syndrome who are not adequately controlled on their current seizure medication. For more information, please visit www.clinicaltrials.gov listing (NCT03355209).
more »Scientific Publications
- Effect of ZX008 on Total Seizures in Dravet Syndrome in a Phase 3 Clinical Trial
- ZX008 in Dravet Syndrome: Effect on Convulsive Seizure Frequency in Subjects Who Failed Treatment with Stiripentol Prior to Study 1, Phase 3 Trial
- ZX008 (Fenfluramine HCl Oral Solution) in Dravet Syndrome: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial